Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer
Interventions: DRUG: Doxorubicin Hydrochloride Liposome Injection
Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Hunan Cancer Hospital|The Second Affiliated Hospital of Chongqing Medical University|First Affiliated Hospital of Jinan University|Zhejiang Provincial People's Hospital|Yuncheng Central Hospital|Shantou Central Hospital|Yuebei People's Hospital|Cancer Hospital of Guizhou Province|Guangzhou Panyu Central Hospital|Dongguan People's Hospital